MA-EXCEL-DRYER
10.9.2020 21:18:12 CEST | Business Wire | Press release
After an exhaustive two-year process, a University of Arizona Health Sciences research team have announced the publication of their work, Comparison of electric hand dryers and paper towels for hand hygiene: a critical review of the literature . The review culled the current breadth of data, including published studies, news reports and online content, seeking to uncover which hand drying method, hand dryers or paper towels, is more hygienic and safer relative to human health risks. The researchers found that, while studies in the public arena generally favor paper towels over hand dryers, the conclusions are largely misleading and unsubstantiated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005927/en/
Through the scientific research, the use of hand dryers and paper towels to dry hands were found to be equal from a health and safety perspective; the findings echo recommendations from the World Health Organization that everyone “frequently clean [their] hands…” and “dry [them] thoroughly by using paper towels or a warm air dryer,” and the Centers for Disease Control and Prevention that report that, “Both [clean towels or air hand dryers] are effective ways to dry hands.”
To conduct the study, the research team considered 293 papers and published studies for inclusion in their review, rejecting 270 for failing to meet review criteria or for reporting generalized recommendations without sufficient scientific evidence. The 23 peer-reviewed studies that met the inclusion criteria were categorized and prioritized based on their scientific rigor, a score determined by taking into account such factors as sample size, methodology, data quality and whether or not the study was set up to represent real-world scenarios.
The study that was found to have the highest rigor score was an independent study conducted by the Mayo Clinic, Effects of 4 Hand-Drying Methods for Removing Bacteria From Washed Hands: A Randomized Trial . It found that “…there is no difference in bacteria counts when drying with paper towels or hand dryers.” Only three studies received positive rigor scores for having realistic testing conditions, and none of the studies reported any negative effects of either hand drying method on human health.
Although numerous studies have been published evaluating the “best” method for hand drying, “best” has been defined in a variety of ways relative to bacterial removal efficacy, environmental contamination potentials, ecological or cost benefits, noise and more. Kelly Reynolds, MSPH, Ph.D., the corresponding author of the review explained that, “No study to date has examined the “best” drying method,” and that she and her team, “found no empirical data to support one hand drying method over another from a health and safety perspective.”
In light of the coronavirus pandemic, hand hygiene has been widely covered in the media. Reynolds shared that, “Media reports frequently used sensationalized headlines. While such headlines may increase traffic, they sometimes overgeneralize or exaggerate research results. Consumers may only read the headlines which can influence public opinion toward biased or erroneous conclusions.”
“At a time when proper hand washing and drying is of the utmost importance, exclusively recommending paper towels is limiting, and frankly, irresponsible,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Hand dryers provide an effective way to achieve completely dry hands, a critical part of proper hand hygiene, the top defense against the spread of germs, like coronavirus.”
The scoping review’s conclusion calls for future studies to examine the relationship between contamination that occurs due to hand-drying methods and human health outcomes. They offer that this can be accomplished by utilizing real-world scenarios while controlling certain variables.
“We hope these credible findings will be consulted as part of guidelines and reopening plans,” said William Gagnon, vice president of marketing and sales at Excel Dryer. “Sensationalized news accounts and click-bait headlines created an unsubstantiated concern around hand dryers and hygiene. We’re grateful to the researchers for uncovering the truth, and hope the findings will help to dispel myths and categorize hand dryers as the hygienic hand drying solution they are.”
About Excel Dryer, Inc.
Excel Dryer has been manufacturing the finest American-made hand dryers for more than 50 years. The family-owned and -operated company revolutionized the industry with the invention of the patented XLERATOR® Hand Dryer that created the high-speed, energy-efficient hand dryer category and set a new standard for performance, reliability and customer satisfaction. Excel Dryer prides itself on offering the best customer service and making hygienic, cost-effective and sustainable products people can depend on. Available for distribution worldwide, Excel Dryer products can be purchased through an established network of sales representatives who call on more than 5,000 distributors globally. Learn more about Excel Dryer at exceldryer.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005927/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
